secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zeo ScientifiX, Inc. (ZEOX)
CIK:        0001557376
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001829126-26-000073
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zeo partners to commercialize Cytora's oral mucosal stem cell therapy under Florida law
--------------------------------------------------------------------------------

- Zeo gets exclusive U.S. commercial rights to Cytora's allogeneic oral mucosal stem cell therapy (hOMSC200).
- Initial commercialization under Florida SB 1768 for diabetic foot ulcers; estimated 125,000 new patients annually in Florida alone.
- Phase 1/2a trial showed favorable safety and statistically significant complete wound closure in 27-month average-open ulcers.
- Made Scientific handles GMP manufacturing at Princeton, NJ; Zeo provides market access, distribution, and clinical site management.
- Partnership also plans U.S. FDA Phase 2b trial aiming for approved license.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557376/000182912626000073/0001829126-26-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557376/000182912626000073/zeoscientifix_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer